In general, the M 2 subtype of muscarinic acetylcholine receptors has the highest sensitivity for allosteric modulators and the M 5 subtype the lowest. The M 2 /M 5 selectivity of some structurally diverse allosteric agents is known to be completely explained by M 2 177 Tyr and M 2 423 Thr in receptors whose orthosteric site is occupied by the conventional ligand N-methylscopolamine (NMS Trp by alanine revealed a pronounced contribution of these epitopes to subtype independent baseline affinity in NMSbound and NMS-free receptors for all agents except diallylcaracurine V. In a few instances, this tryptophan also influenced cooperativity and subtype selectivity. Docking simulations using a three-dimensional M 2 receptor model revealed that the aromatic rings of M 2 177 Tyr and M 2 422 Trp, in a concerted action, might fix one of the aromatic moieties of alkane-bisammonio compounds between them. Thus, M 2 422 Trp and the spatially adjacent M 2 177 Tyr, as well as M 2 423 Thr, form a cluster of amino acids within the allosteric binding cleft that is pivotal for both M 2 /M 5 subtype selectivity and baseline affinity of allosteric agents.All five subtypes of muscarinic acetylcholine receptors contain an allosteric site apart from the orthosteric site that is addressed by acetylcholine and conventional muscarinic agonists and antagonists. Binding of an allosteric modulator allows formation of ternary complexes consisting of the allosteric agent, the orthosteric ligand, and the receptor protein. Through ternary complex formation, allosteric agents may evoke particular actions that cannot be induced by orthosteric ligands alone and that may have therapeutic potential. For instance, allosteric modulators may increase the binding of orthosteric agonists or antagonists (positive cooperativity) or they may inhibit orthosteric ligand binding (negative cooperativity). In either case, the magnitude of the cooperativity will define an intrinsic limit on the magnitude of the positive or negative effect, in marked contrast to the unconstrained action of orthosteric agonists and antagonists. It is also possible for allosteric modulators to leave orthosteric ligand binding unchanged (neutral cooperativity) while nevertheless changing the kinetics of binding (Ellis, 1997;Christopoulos and Kenakin, 2002;Krejčí et al., 2004;Soudijn et al., 2004;Birdsall and Lazareno, 2005;Wess, 2005). Finally, in addition to modulating orthosteric ligand binding properties, allosteric agents also may modulate agonist induced intrinsic efficacy (Zahn et al., 2002). A better understanding of the molecular topology and mechanisms of allosteric